<DOC>
	<DOCNO>NCT02976701</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , double-dummy , control clinical study total 4-week therapy DLBS1033 management STE-ACS primary PCI . There 40 STE-ACS subject ( 20 subject group ) plan complete study .</brief_summary>
	<brief_title>Effect DLBS1033 After Primary PCI Patients With STE-ACS</brief_title>
	<detailed_description>STE-ACS patient undergo intermediate-delayed ( &gt; 3 hour onset STEMI ) primary PCI enrol study . Before intervention , give standard medication PCI . Right PCI , eligible subject assess microvascular perfusion , use pressure-temperature sensor-tipped coronary guidewire . The day , addition dual antiplatelet therapy , i.e . 80 mg aspirin daily clopidogrel 75 mg daily , DLBS1033 dose 490 mg three time daily placebo give subject 4 week . Clinical laboratory examination evaluate investigational drug 's efficacy safety perform Baseline ( right subject undergo primary PCI ) End study ( week 4th DLBS1033 therapy ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>KEY 1 . Signed informed consent . 2 . Men woman 3075 year age . 3 . Evidence acute ST elevation myocardial infarction ( STEMI ) screening , confirm follow : Positive plasma cardiac troponin I [ cTnI ] . Possible ischaemic symptom include various combination chest , upper extremity , mandibular epigastric discomfort ( exertion rest ) ischaemic equivalent dyspnoea fatigue . ECG presentation STEMI . 4 . The onset STEMI &gt; 3 hour undergoing primary PCI . 5 . Therapy study medication start within 24 hour primary PCI . 6 . Able take oral medication . KEY 1 . Females childbearing potential : pregnancy , breastfeed . 2 . History hemorrhagic stroke , serious head injury within last 3 month . 3 . History major surgery within last 6 month . 4 . History PCI CABG . 5 . Evidence previous myocardial infarction . 6 . Ongoing long term need oral anticoagulant , antiplatelets , fibrinolytic , antithrombotic agent , study medication . 7 . Having implant pacemaker cardiac resynchronization therapy ( CRT ) cardiac resynchronization therapy defibrillator ( CRTD ) . 8 . Inadequate liver function 9 . Moderate high risk bleeding ( CRUSADE bleed score &gt; 30 ) 10 . Known suspect allergy study medication , include lumbrokinase product . 11 . Prior experience DLBS1033 oral lumbrokinase product . 12 . Clinical evidence malignancy survival period &lt; 1 year . 13 . Any disease state , include chronic acute systemic infection , uncontrolled illness chronic disease , judge investigator , could interfere trial participation trial evaluation . 14 . Subjects enrol interventional protocol within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>DLBS1033</keyword>
	<keyword>microvascular resistance index</keyword>
	<keyword>Left ventricular function</keyword>
</DOC>